Pfizer Halts Sales of Celebrex in Turkey
- Share via
Pfizer Inc. said it had temporarily halted sales of its pain reliever Celebrex in Turkey because health authorities there sought to include restrictive language concerning cardiovascular issues on its label.
Celebrex is in the same class of drugs as Vioxx, which Merck & Co. pulled from the market in September after studies showed that some users faced a heightened risk of heart attacks.
A spokeswoman for Pfizer said the company hoped that safety studies of that class of drugs by U.S. and European regulators would satisfy Turkey’s concerns.
Shares of New York-based Pfizer fell 11 cents to $26.79 on the New York Stock Exchange.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
